Peter Cohan

Peter Cohan

Peter Cohan is president of Peter S. Cohan & Associates, a management consulting and venture capital firm he founded in 1994. By conducting over 150 consulting projects, he has helped governments and businesses to identify, evaluate and profit from growth opportunities that spring from new technologies. Three of his portfolio companies were sold for a total of $2 billion.

He teaches business strategy to undergraduate and graduate students at Babson College — BusinessWeek ranked its undergraduate strategy department #2 in the U.S.

AchieveMax ranked his eighth book, You Can’t Order Change: Lessons From Jim McNerney’s Turnaround at Boeing, the #1 business book of 2009. His ninth book, co-authored with Srini Rangan, is Capital Rising: How Capital Flows Are Changing Business Systems All Over the World— that Choice called “important, well-researched, socially-responsible, and groundbreaking.”

He has appeared on ABC’s Good Morning America, CBS’s Evening News and Early Show, CNBC, CNN, and PBS’s Nightly Business Report as well as on NPR’s MarketPlace. And he’s been quoted in the New York Times, The Wall Street Journal, Time, BusinessWeek, and Fortune.

Recent Articles

Accenture Could Add To Your Net Worth

ACN has fantastic financial performance, but a market break could be a buying opportunity.

Ulta Can Color Your Portfolio Gold

Rapid earnings growth is reflected in high P/E, but Ulta could grow even faster than expected.

Smithfield Foods Will Nourish Your Net Worth

Stock is pricey, but it’s beating expectations and raising pork prices.

Walter Energy Will Warm Investors’ Wallets

Low P/E-to-earnings growth and possible bidding war for WLT's coal are bullish factors.

Let Brinker Shares Feed Your Portfolio

This company is posting strong earnings reports while keeping costs in check.

Don’t Boo-Hoo for Bartz’s Ouster at Yahoo

Bartz cut costs during her tenure -- and now her departure could lead to a Yahoo sale or possibly usher in an innovative CEO.

Don’t Slurp Your Campbell Soup

Campbell is making the right moves when it comes to cost cutting and innovation. Here's a look at whether it's time to buy CPB stock.

CVS Is No Rx For Your Portfolio

CVS has an impressive income statement, but it is not using capital efficiently. A drop in price or surprisingly good earnings growth, however, might merit a buy.

Power Your Portfolio With National Grid

Despite somewhat high valuation, its whopping dividend yield and profit margin make this utility attractive.

Expeditors International: Proven, But Pricey

EXPD's high valuation means you should wait until this solid performer’s stock price falls.